Loading clinical trials...
Loading clinical trials...
Ozanimod (Zeposia®) In Patients With RRMS: A 3-Year, Multicenter, Prospective, Non-Interventional Study to Document Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany (OZEAN)
The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as quality of life, effectiveness, and incidence of adverse events.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Universitätsklinikum Dresden, MS Ambulanz
Dresden, Saxony, Germany
Start Date
March 3, 2021
Primary Completion Date
June 30, 2025
Completion Date
June 30, 2025
Last Updated
September 8, 2025
450
ACTUAL participants
Ozanimod
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT05359653
NCT06390930
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions